Daniel Curran
Director/Board Member bei XILIO THERAPEUTICS, INC.
Profil
Daniel Curran is currently an Independent Director at Xilio Therapeutics, Inc., a Director at Stargazer Pharmaceuticals, Inc., a Director at Oak Hill Bio Corp., and a Director at Tome Biosciences, Inc. Previously, he held the position of Vice President-Business & Corporate Development at Millennium Pharmaceuticals, Inc. from 1999 to 2012.
He also worked as a Senior VP, Head-Rare Genetics & Hematology at Takeda Pharmaceutical Co., Ltd.
and as a Principal at DuPont Merck Pharmaceutical Co. Dr. Curran received his undergraduate degree from King's College (Pennsylvania), his MBA from The Wharton School of the University of Pennsylvania, and his doctorate from the University of Pennsylvania Medical Center.
Aktive Positionen von Daniel Curran
| Unternehmen | Position | Beginn |
|---|---|---|
| XILIO THERAPEUTICS, INC. | Director/Board Member | 01.12.2020 |
Stargazer Pharmaceuticals, Inc.
 Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Director/Board Member | 01.01.2019 |
Oak Hill Bio Corp.
 Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Director/Board Member | 12.04.2022 |
Tome Biosciences, Inc.
 Tome Biosciences, Inc. BiotechnologyHealth Technology Tome Biosciences, Inc. provides genomic medicine insertion and technologies services. The company is based in Cambridge, MA. The CEO of the company is Rahul Kakkar. | Director/Board Member | - |
Ehemalige bekannte Positionen von Daniel Curran
| Unternehmen | Position | Ende |
|---|---|---|
Millennium Pharmaceuticals, Inc.
 Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01.10.2012 |
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Corporate Officer/Principal | - |
DuPont Merck Pharmaceutical Co.
 DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Corporate Officer/Principal | - |
Ausbildung von Daniel Curran
| King's College (Pennsylvania) | Undergraduate Degree |
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| University of Pennsylvania Medical Center | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Börsennotierte Unternehmen | 2 |
|---|---|
| TAKEDA PHARMACEUTICAL COMPANY LIMITED | Health Technology |
| XILIO THERAPEUTICS, INC. | Health Technology |
| Private Unternehmen | 5 |
|---|---|
Millennium Pharmaceuticals, Inc.
Millennium Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Millennium Pharmaceuticals, Inc. operates as a biopharmaceutical company. Its products include Ninlaro and Velcade. The company was founded in 1993 and is headquartered in Cambridge, MA. | Health Technology |
DuPont Merck Pharmaceutical Co.
DuPont Merck Pharmaceutical Co. Pharmaceuticals: MajorHealth Technology Part of Corteva, Inc., DuPont Merck Pharmaceutical Co. is a private company that makes pharmaceuticals and drugs. The company is based in Wilmington, DE. DuPont Merck Pharmaceutical was acquired by EIDP, Inc., a subsidiary of Corteva, Inc. from Merck & Co., Inc. on July 01, 1998 for $2,600 million. | Health Technology |
Stargazer Pharmaceuticals, Inc.
Stargazer Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Stargazer Pharmaceuticals, Inc. manufactures pharmaceutical products. The firm engages in the development of treatment for Stargardt’s disease, a rare form of juvenile, retinal degeneration. The company was founded by Gary Jay Sternberg and is headquartered in Boston, MA. | Health Technology |
Tome Biosciences, Inc.
Tome Biosciences, Inc. BiotechnologyHealth Technology Tome Biosciences, Inc. provides genomic medicine insertion and technologies services. The company is based in Cambridge, MA. The CEO of the company is Rahul Kakkar. | Health Technology |
Oak Hill Bio Corp.
Oak Hill Bio Corp. Miscellaneous Commercial ServicesCommercial Services Oak Hill Bio, Inc. is a clinical-stage rare disease therapeutics company. It develops life-changing medicines for extremely preterm infants and patients suffering from rare autoimmune diseases. The firm has operations in the United States and United Kingdom to develop a pipeline of clinical-stage and pre-clinical investigational therapeutics acquired and licensed from Takeda Pharmaceutical Company Limited. The company is headquartered in Cambridge, MA. | Commercial Services |
